tyrosine kinase inhibitor
Small moleculeexperimental
A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The proteins are activated by adding a phosphate group to the protein (phosphorylation), a step that TKIs inhibit. TKIs are typically used as anticancer drugs. For example, they have substantially improved outcomes in chronic myelogenous leukemia. They have also been used to treat other diseases, such as idiopathic pulmonary fibrosis. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 5, 2018 (NCT03799094)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTyrosine kinase inhibitor ↗
Also known as
- tyrosine kinase inhibitor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04006847 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2019 | Pennsylvania State University |
| NCT03799094 | Phase 1/Phase 2 (Phase 2) | Dec 5, 2018 | Clifford Hospital, Guangzhou, China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clifford Hospital, Guangzhou, China | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Pennsylvania State University | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1